Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma

NCT05308654 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05308654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05308654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 17, 2022
Completion date
December 31, 2025
Enrollment
34 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma